Prognostic Value of BNP in MCS - a 25 Year Follow up Study
Recruiting · NCT04377854 · Observational (researchers observe without assigning treatment) · Lead sponsor: Rigshospitalet, Denmark
View the official record on ClinicalTrials.gov →Interventions studied
2) Observation and collection and of blood sampleObservation. No intervention per se.
What this trial is about
A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy. Patients will be followed up for 25 years after inclusion.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- All patients referred for evaluation for advanced HF treatment at the Rigshospital in Denmark
- Age\>18 years
Exclusion criteria
- No consent
Where it is running
1 location listed.
- Rigshospitalet - Copenhagen, DK, Denmark